Royce & Associates LP Invests $7.21 Million in ADMA Biologics, Inc. (NASDAQ:ADMA)

Royce & Associates LP acquired a new stake in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 420,569 shares of the biotechnology company's stock, valued at approximately $7,213,000. Royce & Associates LP owned about 0.18% of ADMA Biologics at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Natixis Advisors LLC acquired a new position in ADMA Biologics in the 3rd quarter valued at about $345,000. Mutual of America Capital Management LLC bought a new position in shares of ADMA Biologics during the third quarter worth approximately $701,000. Thrivent Financial for Lutherans bought a new position in shares of ADMA Biologics during the third quarter worth approximately $3,802,000. First Turn Management LLC acquired a new stake in ADMA Biologics during the 3rd quarter worth approximately $13,293,000. Finally, Aviance Capital Partners LLC bought a new stake in ADMA Biologics in the 3rd quarter valued at $229,000. 75.68% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Separately, Cantor Fitzgerald reiterated an "overweight" rating and set a $25.00 price objective on shares of ADMA Biologics in a research report on Tuesday, March 4th.

ADMA Biologics Price Performance

Shares of NASDAQ ADMA traded up $0.15 during midday trading on Friday, reaching $19.80. The company's stock had a trading volume of 8,551,656 shares, compared to its average volume of 3,365,738. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09. The company has a market cap of $4.68 billion, a P/E ratio of 70.71 and a beta of 0.60. The business's 50 day moving average price is $16.76 and its two-hundred day moving average price is $18.03. ADMA Biologics, Inc. has a fifty-two week low of $5.90 and a fifty-two week high of $23.64.

Remove Ads

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.